Cargando…

Pleural Tuberculosis following Infliximab Therapy for Ankylosing Spondylitis

We present a case of pleural tuberculosis (TB) in a patient on infliximab for ankylosing spondylitis. A 36-year-old male presented to our hospital with low back ache of inflammatory type along with multiple symmetric inflammatory type of joint pain. Further clinical examination, laboratory and radio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krishnan, V. S. Gokul, Madhyastha, Sharath, Ramamoorthi, Kusugodlu, Acharya, Raviraj V., Gopalaswamy, Vinaya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370330/ https://www.ncbi.nlm.nih.gov/pubmed/28405137 http://dx.doi.org/10.4103/jpp.JPP_174_16

Ejemplares similares

Infliximab in the treatment of ankylosing spondylitis
por: Grainger, Rebecca, et al.
Publicado: (2007)

Management of ankylosing spondylitis with infliximab
por: Toussirot, Éric, et al.
Publicado: (2009)

Leukocytoclastic Vasculitis: A peculiar presentation of scrub typhus
por: Vasireddy, Anila, et al.
Publicado: (2023)

Looking beyond the Obvious: Cefepime-induced Nonconvulsive Status Epilepticus
por: Anuhya, Vinayaka, et al.
Publicado: (2017)

Cerebral Tuberculosis in a Patient Following Treatment With Infliximab for Ankylosing Spondylitis: A Case Report
por: Cretu, Ioana, et al.
Publicado: (2023)

Phlegmonous gastritis in an ankylosing spondylitis patient treated with infliximab
por: Kim, Bo Young, et al.
Publicado: (2017)

Phlegmonous gastritis in an ankylosing spondylitis patient treated with infliximab
por: Kim, Bo Young, et al.
Publicado: (2017)

Body mass index influences the response to infliximab in ankylosing spondylitis
por: Ottaviani, Sébastien, et al.
Publicado: (2012)

Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis
por: Elalouf, Ofir, et al.
Publicado: (2015)

Bone changes and curative effect of infliximab in patients with ankylosing spondylitis
por: Li, Linying, et al.
Publicado: (2020)

A Clinical and Demographic Profile of Elderly (>65 Years) in the Medical Intensive Care Units of a Tertiary Care Center
por: Prabhudev, Pruthvi, et al.
Publicado: (2023)

Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab
por: Lorenzin, Mariagrazia, et al.
Publicado: (2015)

Effects of etanercept and infliximab on bone metabolism indexes in patients with ankylosing spondylitis
por: Wang, Chenghai, et al.
Publicado: (2020)

Adaptive Immunity in Ankylosing Spondylitis: Phenotype and Functional Alterations of T-Cells before and during Infliximab Therapy
por: Szalay, Balázs, et al.
Publicado: (2012)

Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study
por: Moreno, Mireia, et al.
Publicado: (2019)

Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
por: Mulleman, Denis, et al.
Publicado: (2011)

Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness‐to‐Pay Approach
por: Webers, Casper, et al.
Publicado: (2018)

Disseminated Tuberculosis Mimicking Ankylosing Spondylitis
por: Huyge, Valérie, et al.
Publicado: (2011)

Ankylosing spondylitis
Publicado: (1980)

Ankylosing spondylitis
por: Edavalath, Mukesh
Publicado: (2010)

Ankylosing Spondylitis
por: Whitfield, A. G. W.
Publicado: (1976)

Ankylosing Spondylitis
por: Ebrahimiadib, Nazanin, et al.
Publicado: (2021)

Influence of a polymorphism IL1B gene in the response of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab
por: Morales-Lara, M J, et al.
Publicado: (2010)

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
por: Baraliakos, Xenofon, et al.
Publicado: (2005)

Predicting the outcome of ankylosing spondylitis therapy
por: Vastesaeger, Nathan, et al.
Publicado: (2011)

Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab
por: Visvanathan, S, et al.
Publicado: (2008)

Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis
por: Visvanathan, S, et al.
Publicado: (2008)

Regulation of peripheral classical and non-classical monocytes on infliximab treatment in patients with rheumatoid arthritis and ankylosing spondylitis
por: Aeberli, Daniel, et al.
Publicado: (2016)

Correction: Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
por: Baraliakos, Xenofon, et al.
Publicado: (2005)

A case study: consequences of ANTI-TNFα therapy and foot ulcerations. A patient with Ankylosing Spondylitis (AS) treated with Infliximab
por: Edgson, Lucy, et al.
Publicado: (2010)

Ankylosing Spondylitis and Rheumatoid Arthritis: Serum Levels of TNF-α and Its Soluble Receptors during the Course of Therapy with Etanercept and Infliximab
por: Schulz, Martin, et al.
Publicado: (2014)

Imaging of ankylosing spondylitis
por: Østergaard, Mikkel
Publicado: (2012)

Alexithymia in ankylosing spondylitis
por: Karabıçak, Deniz, et al.
Publicado: (2021)

Long-term efficiency of infliximab in patients with ankylosing spondylitis: real life data confirm the potential for dose reduction
por: Baraliakos, X, et al.
Publicado: (2016)

Role of TRAILR1 and TNFR1A polymorphisms in the susceptibility and pharmacogenetics of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab
por: Morales-Lara, M J, et al.
Publicado: (2010)

Anti-TNF-α Therapy for Ankylosing Spondylitis
por: Son, Jung-Hwan, et al.
Publicado: (2010)

Clinical response to discontinuation of anti-tumor necrosis factor therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
por: Baraliakos, X, et al.
Publicado: (2005)

The Role of MicroRNAS in Ankylosing Spondylitis
por: Li, Zheng, et al.
Publicado: (2016)

Clinical response to the anti-tumor necrosis factor alpha antibody infliximab in patients with ankylosing spondylitis over 3 years
por: Baraliakos, X, et al.
Publicado: (2005)

Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumor necrosis factor alpha antibody infliximab
por: Baraliakos, X, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_bqtd6ocpen9q50bvc1hjahmk0p